Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029

Loading news article.

Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029 | WAPE

Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029

Article summary

Related companies

Comments —